CRISPR Therapeutics AG (CRSP) EBIT (2015 - 2026)

CRISPR Therapeutics AG has disclosed EBIT across 12 years of filings, most recently posting -$130.2 million for Q1 2026.

• EBIT for Q1 2026 came in at -$130.2 million, up 12.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$646.4 million (down 36.25% YoY), and the FY2025 annual result was -$664.6 million, down 42.44% from the prior year.
• EBIT came in at -$130.2 million for Q1 2026 at CRISPR Therapeutics AG, up from -$154.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $69.6 million in Q4 2023 to a low of -$229.3 million in Q2 2025.
• The 5-year median for EBIT is -$132.4 million (2023), against an average of -$126.9 million.
• Across the five-year window, EBIT surged 152.9% in 2023 and tumbled 192.82% in 2024, its largest moves.
• CRISPR Therapeutics AG's EBIT stood at -$131.5 million in 2022, then jumped by 152.9% to $69.6 million in 2023, then sank by 192.82% to -$64.6 million in 2024, then plunged by 139.62% to -$154.8 million in 2025, then increased by 15.84% to -$130.2 million in 2026.
• The last three EBIT figures came in at -$130.2 million (Q1 2026), -$154.8 million (Q4 2025), and -$132.1 million (Q3 2025), per Business Quant data.